# A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

> **NCT02872714** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 263 (actual)

## Conditions studied

- UC (Urothelial Cancer)

## Interventions

- **DRUG:** pemigatinib
- **DRUG:** pemigatinib

## Key facts

- **NCT ID:** NCT02872714
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-12
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-02-01
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02872714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02872714, "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02872714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*